Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (18)

2024

  1. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient

    International Journal of Drug Policy, Vol. 130

  2. Cocaine Effect Expectancies among Patients with Cocaine Use Disorder with and without Adult Attention Deficit Hyperactivity Disorder: Are There Any Relevant Differences?

    Journal of Psychoactive Drugs, Vol. 56, Núm. 1, pp. 76-87

  3. Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia

    Schizophrenia Research, Vol. 267, pp. 24-31

  4. Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations

    Schizophrenia Research, Vol. 267, pp. 534-545

2023

  1. The polygenic basis of relapse after a first episode of schizophrenia

    European Neuropsychopharmacology, Vol. 75, pp. 80-92

2022

  1. Epigenetic clocks in relapse after a first episode of schizophrenia

    Schizophrenia, Vol. 8, Núm. 1

  2. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

    Schizophrenia, Vol. 8, Núm. 1

  3. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

    European Neuropsychopharmacology, Vol. 57, pp. 105-117

2021

  1. A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood

    Translational Psychiatry, Vol. 11, Núm. 1

  2. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 164-176

2020

  1. Towards a common metric for assessing heroin-dependent patient satisfaction with medications: Testing methadone and buprenorphine-naloxone

    Drug and Alcohol Dependence, Vol. 212

2018

  1. A cluster-analytic profiling of heroin-dependent patients based on level, clinical adequacy, and patient-desired adjustment of buprenorphine dosage during buprenorphine-naloxone maintenance treatment in sixteen Spanish centers

    Drug and Alcohol Dependence, Vol. 187, pp. 278-284

  2. Development and validation of the scale to assess satisfaction with medications for addiction treatment – Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER)

    International Journal of Drug Policy, Vol. 58, pp. 126-134

  3. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment

    Drug and Alcohol Dependence, Vol. 183, pp. 127-133

2017

  1. Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions

    Patient Education and Counseling, Vol. 100, Núm. 5, pp. 981-986

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481